PMID- 34908240
OWN - NLM
STAT- MEDLINE
DCOM- 20220920
LR  - 20240320
IS  - 1743-7563 (Electronic)
IS  - 1743-7555 (Print)
IS  - 1743-7555 (Linking)
VI  - 18
IP  - 5
DP  - 2022 Oct
TI  - Efficacy, toxicity, and quality-of-life outcomes of ultrahypofractionated 
      radiotherapy in patients with localized prostate cancer: A single-arm phase 2 
      trial from Asia.
PG  - e346-e355
LID - 10.1111/ajco.13742 [doi]
AB  - AIMS: Ultra-hypofractionated radiotherapy (UHF-RT) is widely utilized in men with 
      localized prostate cancer (PCa). There are limited data in Asian cohorts. We 
      report the outcomes of a single-arm, phase II trial of UHF-RT from an Asian 
      center. METHODS: We recruited men with histologically confirmed, nonmetastatic 
      localized PCa. UHF-RT regimens were 36.25 Gy (Cohort A) and 37.5 Gy (Cohort B) 
      delivered in five fractions every other day over 1.5-2.5 weeks. Primary endpoint 
      was physician-scored late genitourinary (GU) and gastrointestinal (GI) adverse 
      events (AEs). Quality-of-life (QoL) was assessed by Expanded Prostate Cancer 
      Index Composite (EPIC) at baseline, 1- and 2-year post-UHF-RT. RESULTS: Between 
      March 2014 and August 2019, 105 men were recruited; four were subsequently 
      excluded from analysis. Median age was 68.0 (Interquartile range (IQR): 
      63.8-73.0) years. 26 (24.8%) and 68 (64.8%) men had NCCN-defined low-and 
      intermediate-risk PCa, respectively. No late >/=G3 GU or GI toxicities were 
      reported in both cohorts. Peak incidence of acute >/=G2 GU AEs at 14 days 
      post-UHF-RT was 23.6% (17/72) and 24.0% (6/25) in Cohorts A and B, respectively; 
      >/=G2 GI AEs were observed in 9.7% (7/72) and 36.0% (9/25), respectively. Late >/=G2 
      GU and GI AEs occurred in 4.7% and 3.1% of Cohort A patients, and 5.0% in Cohort 
      B at 12 months, with no AEs at 24 months. EPIC scores changed minimally across 
      all domains. At a median follow-up of 44.9 months, we recorded one (1.3%) 
      biochemical relapse by the Phoenix criteria (Cohort A). CONCLUSION: UHF-RT is 
      well tolerated in Asian men and can be a recommended fractionation schema for 
      localized PCa.
CI  - (c) 2021 The Authors. Asia-Pacific Journal of Clinical Oncology published by John 
      Wiley & Sons Australia, Ltd.
FAU - Tan, Janice S H
AU  - Tan JSH
AUID- ORCID: 0000-0002-7011-2740
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
FAU - Teh, Jonathan Y H
AU  - Teh JYH
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
AD  - Asian Alliance Radiation Oncology Centre, Singapore.
FAU - Tan, Laura L Y
AU  - Tan LLY
AUID- ORCID: 0000-0003-4735-5522
AD  - Ministry of Health Holdings, Singapore.
FAU - Tan, Sheena X F
AU  - Tan SXF
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
FAU - Li, You Quan
AU  - Li YQ
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
FAU - Tan, Terence W K
AU  - Tan TWK
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
AD  - Duke University and National University of Singapore (Duke-NUS) Medical School, 
      Singapore.
FAU - Wang, Michael L C
AU  - Wang MLC
AUID- ORCID: 0000-0001-7882-8957
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
AD  - Duke University and National University of Singapore (Duke-NUS) Medical School, 
      Singapore.
FAU - Kanesvaran, Ravindran
AU  - Kanesvaran R
AD  - Duke University and National University of Singapore (Duke-NUS) Medical School, 
      Singapore.
AD  - Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
FAU - Ong, Enya H W
AU  - Ong EHW
AUID- ORCID: 0000-0002-2591-7910
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
AD  - Division of Medical Sciences, National Cancer Centre Singapore, Singapore.
FAU - Tay, Kae Jack
AU  - Tay KJ
AD  - Duke University and National University of Singapore (Duke-NUS) Medical School, 
      Singapore.
AD  - Department of Urology, Singapore General Hospital, Singapore.
FAU - Lee, Lui Shiong
AU  - Lee LS
AUID- ORCID: 0000-0002-8208-0635
AD  - Duke University and National University of Singapore (Duke-NUS) Medical School, 
      Singapore.
AD  - Department of Urology, Seng Kang General Hospital, Singapore.
FAU - Tuan, Jeffrey K L
AU  - Tuan JKL
AUID- ORCID: 0000-0002-4353-8439
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
AD  - Duke University and National University of Singapore (Duke-NUS) Medical School, 
      Singapore.
FAU - Tan, Daniel Y H
AU  - Tan DYH
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
AD  - Asian Alliance Radiation Oncology Centre, Singapore.
FAU - Chua, Melvin L K
AU  - Chua MLK
AUID- ORCID: 0000-0002-1648-1473
AD  - Division of Radiation Oncology, National Cancer Centre Singapore, Singapore.
AD  - Duke University and National University of Singapore (Duke-NUS) Medical School, 
      Singapore.
AD  - Division of Medical Sciences, National Cancer Centre Singapore, Singapore.
LA  - eng
GR  - National Cancer Centre of Singapore/
GR  - Duke-NUS Medical School/
GR  - Ministry of Education - Singapore/
GR  - National Research Foundation/
GR  - National Medical Research Council/
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20211214
PL  - Australia
TA  - Asia Pac J Clin Oncol
JT  - Asia-Pacific journal of clinical oncology
JID - 101241430
SB  - IM
MH  - Aged
MH  - Dose Fractionation, Radiation
MH  - *Gastrointestinal Diseases/etiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Prostatic Neoplasms/pathology/radiotherapy
MH  - Quality of Life
MH  - Radiation Dose Hypofractionation
MH  - *Radiotherapy, Intensity-Modulated/adverse effects
PMC - PMC10946613
OTO - NOTNLM
OT  - Asian
OT  - intermediate-risk
OT  - localized prostate cancer
OT  - stereotactic body radiotherapy
OT  - ultrahypofractionated radiotherapy
COIS- Melvin L.K. Chua reports personal fees from Astellas, Janssen, Bayer, Pfizer, 
      MSD, personal fees and nonfinancial support from AstraZeneca, personal fees and 
      grants from Ferring, personal fees and nonfinancial support from Varian, 
      nonfinancial support from Decipher Biosciences, nonfinancial support from 
      MedLever, and consults for immunoSCAPE Inc., outside the submitted work. All 
      other authors declare no conflict of interest.
EDAT- 2021/12/16 06:00
MHDA- 2022/09/21 06:00
PMCR- 2024/03/18
CRDT- 2021/12/15 09:05
PHST- 2021/09/19 00:00 [received]
PHST- 2021/11/07 00:00 [accepted]
PHST- 2021/12/16 06:00 [pubmed]
PHST- 2022/09/21 06:00 [medline]
PHST- 2021/12/15 09:05 [entrez]
PHST- 2024/03/18 00:00 [pmc-release]
AID - AJCO13742 [pii]
AID - 10.1111/ajco.13742 [doi]
PST - ppublish
SO  - Asia Pac J Clin Oncol. 2022 Oct;18(5):e346-e355. doi: 10.1111/ajco.13742. Epub 
      2021 Dec 14.